Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Response and survival, trial by trial.

Each card is one trial arm. A bar is a response percent the source states. Progression-free survival, overall survival, and a hazard ratio stay in the units the source used. This page does not subtract one arm from another.

10 arms have a reported figure in this set.

Amivantamab 1

Amivantamab

Amivantamab

not stated in source · Single arm

ACC (n = 21)

median progression-free survival: 4.6 months, results posted 05.08.2026

Amivantamab in ACC · NCT05074940

Axitinib (off Label) 5

Emiltatug Ledadotin (Emi-Le, XMT-1660) 1

Lenvatinib (off Label) 2

Lenvatinib (off Label)

Lenvatinib 24 mg

24 mg · Single arm

R/M salivary ACC (n = 26 evaluable)

median progression-free survival: 9.1 months, primary analysis

ACC-LEN14 · NCT02860936

Rivoceranib 1

Rivoceranib

Rivoceranib 700 mg

700 mg · Single arm

R/M ACC (n = 80; 72 evaluable)

median progression-free survival: 9 months, primary analysis

Rivoceranib Phase 2 · NCT04119453

A note on interpreting comparisons: this page lines up results from different trials so the broader evidence is visible. Treat a gap between arms as context. A randomized trial that assigns the treatments in the same study is the strongest comparison.